Roche Diagnostics secured FDA clearance for a molecular vaginitis assay designed to detect pathogens associated with bacterial vaginosis and Candida vaginitis using clinician-collected or self-collected vaginal swabs. The clearance adds to Roche’s diagnostics footprint in women’s health by enabling molecular testing workflows that can be used with home-collection approaches. The assay’s design supports clinical settings where specimen logistics and faster organism identification are key to treatment decisions. For clinicians and health systems, the key operational impact is the ability to pair sampling flexibility with targeted pathogen detection rather than relying on less specific testing strategies. For Roche, the clearance expands its molecular assay portfolio and strengthens differentiation in point-of-care-adjacent women’s health diagnostics where reimbursement and adoption will be closely watched.